Homocysteine

What is Homocysteine?

Homocysteine is an amino acid your body normally clears using vitamins B6, B12, and folate.

Homocysteine is a byproduct your body makes constantly as it breaks down methionine, an amino acid you get from protein in food. In a well-supplied body, three vitamins working in sequence, B6, B12, and folate, recycle homocysteine back into other compounds almost as fast as it's produced. When any one of those three is running low, the recycling slows down and homocysteine builds up in the blood. That's the whole mechanism, and it's also the source of the test's biggest limitation: a high result tells you the clearing system is backed up, not which vitamin caused the backup. Vitamin B12 (Cobalamin) testing, Folate (Serum) testing, and vitamin B6 testing exist precisely because homocysteine alone can't tell them apart. A related marker, Methylmalonic Acid (MMA), rises with a B12 shortage but not with low folate or B6, which is why doctors often order it alongside homocysteine when B12 deficiency is suspected but folate or B6 status is unclear. Homocysteine's other, larger story is about the heart. Through the 1990s and into the 2000s, researchers noticed that people with higher homocysteine levels also had more atherosclerosis, heart attacks, and strokes, and a hypothesis took hold that homocysteine itself was damaging blood vessel walls. If that were true, lowering it with B vitamins, which are cheap and low-risk, should prevent cardiovascular events. Three large randomized trials tested that directly. The 2006 HOPE-2 trial gave 5,522 people with existing vascular disease or diabetes a combination of folic acid, B6, and B12 for five years; it lowered homocysteine as expected but didn't reduce the combined rate of cardiovascular death, heart attack, or stroke (relative risk 0.95, not statistically significant), though a secondary look at stroke alone did show a reduction. The NORVIT trial, in 3,749 heart attack survivors, found no benefit either, and one combination arm trended toward more events. VISP, in stroke patients, lowered homocysteine by an extra 2 µmol/L in the high-dose group with no difference in recurrent stroke risk. Taken together, these trials are why doctors stopped treating homocysteine as something to routinely test and correct for heart disease prevention: the correlation held up in observational data, but fixing the number didn't change outcomes. In rare cases, homocysteine climbs far above the typical range, above 100 µmol/L, from homocystinuria, an inherited condition affecting how the body processes methionine. That's a genetics and metabolism question for a specialist, not something a single elevated result on its own suggests.

Typical reference context

Ranges vary by lab and assay. Source: Cleveland Clinic, reviewed January 2025; Association for Diagnostics & Laboratory Medicine (ADLM) optimal test utilization guide, reviewed March 2023.

What changed recently

The heart-disease question didn't stay fully closed. A November 2025 systematic review and meta-analysis in BMC Nutrition, pooling 45 randomized trials and nearly 97,000 participants, found that folic acid supplementation was associated with a modest but statistically significant 15% reduction in stroke risk (RR 0.85), while showing no effect on coronary heart disease, overall mortality, or peripheral arterial disease. The authors suggest cerebral blood vessels may be more sensitive to homocysteine-related effects than coronary arteries, which would explain why the original trials, several of which combined stroke and heart attack into one outcome, came back null. A separate September 2025 review in the Journal of Cardiovascular Development and Disease reached a consistent bottom line: homocysteine still works better as a passive risk marker than a treatment target, and current guidance reserves testing for narrow scenarios, like unexplained stroke in a young person, vascular disease without the usual risk factors, or recurrent pregnancy loss, rather than routine cardiovascular screening. On the kidney-disease question, a February 2025 study in Nutrients following 297 people with chronic kidney disease for a median of four years found homocysteine's link to cardiovascular events disappeared once age, sex, and kidney function were accounted for, suggesting the elevation in CKD is more a byproduct of reduced kidney clearance than an independent driver of risk.

Tests often checked alongside this

Homocysteine rarely stands alone. When it's elevated, doctors typically add Vitamin B12 (Cobalamin), Folate (Serum), and sometimes Methylmalonic Acid (MMA) to work out which part of the clearing system is short, since homocysteine's rise looks the same regardless of which vitamin caused it. In someone with reduced kidney function, homocysteine is often interpreted alongside kidney markers rather than vitamin panels, since impaired clearance alone can push the number up.

What to ask your doctor

• Given this result, would checking B12, folate, and B6 individually help narrow down the cause?
• Does my kidney function affect how this number should be read?
• Is there a specific reason you're ordering this test for me, given that it's not part of routine heart-disease screening?

This glossary entry is for informational purposes only and is not a substitute for professional medical advice. Read our Terms of Use.

Frequently asked questions